Friday, January 31, 2020
With genomic sequencing on the rise and patients having more say about their treatment, two hot areas—predictive genetic testing and pharmacogenomics—promise to extend “personalized” medicine beyond cancer care. But will this precision improve outcomes and pay for itself? Susanne Haga weighs in.